Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empirical treatment of healthcare-associated pneumonia
2009-016476-67Phase 4Active
- Sponsor
- Azienda Ospedaliero-Universitaria Policlinico Umberto I
- Start
- Nov 2009
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of piperacillin + tazobactam, imipenem, meropenem, vancomycin, linezolid and 3 more in Healthcare-associated pneumonia (HCAP) (2 arms), sponsored by Azienda Ospedaliero-Universitaria Policlinico Umberto I. Primary endpoint: In-hospital mortality. Started Nov 2009; status: active.
02
Drugs
piperacillin + tazobactamimipenemmeropenemvancomycinlinezolid
03
Conditions
Healthcare-associated pneumonia (HCAP)
Beyond the preview
Go deeper on 2009-016476-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016476-67.